Volume 7, Issue 2 (11-2021)
Journal of Research in Applied and Basic Medical Sciences 2021, 7(2): 76-85 |
Back to browse issues page
Southwest College of Naturopathic Medicine and Health Sciences - Arizona – United States , : s.shahabi@scnm.edu
Abstract: (1733 Views)
Background: Salmonella typhimurium (S. typhimurium) is one of the causative agents of intestinal and extraintestinal infections in humans. Symptoms of the mouse infection by this bacterium mimic typhoid fever in humans. Adjuvants are compounds that enhance the effectiveness of vaccines in combination with them. Alum as an adjuvant causes a shift towards Th2 immune and strengthens the humoral immunity responses. Cisplatin is a highly effective anti-tumor drug that stimulates immune responses by activating macrophages and other immune cells and is used in tumor immunotherapy. This study aimed to investigate the role of cisplatin and the cisplatin-alum mixture as adjuvants to increase the efficacy of vaccination against S. typhimurium in Balb/c mice.
Methods: Male BALB/c mice were divided into five groups. Mice in the experimental groups received either the HKST vaccine alone or in combination with the adjuvants alum, cisplatin, or the cisplatin-alum. Mice in the negative control group received phosphate-buffered saline. All mice were immunized two times on days 0 and 14. Two weeks after the last immunization, immune responses to S. typhimurium were assessed by measuring the survival rate after challenge with a lethal dose of bacterium, bacterial load in the liver, interferon-gamma, and S. typhimurium-specific IgG1 and IgG2a production.
Results: The numbers of colonies in the spleen and liver cultures in all dilutions were significantly lower in cisplatin-vaccine, and cisplatin-alum vaccine immunized mice. The average rate of specific IgG2a was higher in the same groups compared to other groups. The survival rate in alum-vaccine, cisplatin-vaccine, and cisplatin-alum-vaccine groups was significantly higher than in the control group. The average rate of Interferon-gamma in cisplatin-vaccine and cisplatin- alum vaccine groups, was significantly higher than other groups.
Conclusion: This study is the first to determine the role of administrating cisplatin and alum-cisplatin mixture on increasing the efficiency of the HKST vaccine in a mouse model. This study confirmed the role of cisplatin and cisplatin-alum mixture in increasing the efficiency of the HKST vaccine by using different experiments.
Methods: Male BALB/c mice were divided into five groups. Mice in the experimental groups received either the HKST vaccine alone or in combination with the adjuvants alum, cisplatin, or the cisplatin-alum. Mice in the negative control group received phosphate-buffered saline. All mice were immunized two times on days 0 and 14. Two weeks after the last immunization, immune responses to S. typhimurium were assessed by measuring the survival rate after challenge with a lethal dose of bacterium, bacterial load in the liver, interferon-gamma, and S. typhimurium-specific IgG1 and IgG2a production.
Results: The numbers of colonies in the spleen and liver cultures in all dilutions were significantly lower in cisplatin-vaccine, and cisplatin-alum vaccine immunized mice. The average rate of specific IgG2a was higher in the same groups compared to other groups. The survival rate in alum-vaccine, cisplatin-vaccine, and cisplatin-alum-vaccine groups was significantly higher than in the control group. The average rate of Interferon-gamma in cisplatin-vaccine and cisplatin- alum vaccine groups, was significantly higher than other groups.
Conclusion: This study is the first to determine the role of administrating cisplatin and alum-cisplatin mixture on increasing the efficiency of the HKST vaccine in a mouse model. This study confirmed the role of cisplatin and cisplatin-alum mixture in increasing the efficiency of the HKST vaccine by using different experiments.
Type of Study: orginal article |
Subject:
Special
References
1. Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw 2015;15(2):51-7. [DOI:10.4110/in.2015.15.2.51]
2. Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO molecular medicine 2014;6(6):708-20. [DOI:10.1002/emmm.201403876]
3. Cunningham AL, Garcon N, Leo O, Friedland LR, Strugnell R, Laupeze B, et al. Vaccine development: From concept to early clinical testing. Vaccine 2016;34(52):6655-64 [DOI:10.1016/j.vaccine.2016.10.016]
4. Apostolico Jde S, Lunardelli VA, Coirada FC, Boscardin SB, Rosa DS. Adjuvants: Classification, Modus Operandi, and Licensing. J Immunol Res 2016;2016:1459394. [DOI:10.1155/2016/1459394]
5. Jazani NH, Sohrabpour M, Mazloomi E, Shahabi S. A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. FEMS Immunol Med Microbiol 2011;61(1):54-62. [DOI:10.1111/j.1574-695X.2010.00747.x]
6. Gupta RK, Rost BE, Relyveld E, Siber GR. Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol 1995;6:229-48. [DOI:10.1007/978-1-4615-1823-5_8]
7. Lambrecht BN, Kool M, Willart MA, Hammad H. Mechanism of action of clinically approved adjuvants. Curr Opin Immunol 2009;21(1):23-9. [DOI:10.1016/j.coi.2009.01.004]
8. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009;9(4):287-93. [DOI:10.1038/nri2510]
9. Ghimire TR, Benson RA, Garside P, Brewer JM. Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro. Immunol Lett 2012;147(1-2):55-62. [DOI:10.1016/j.imlet.2012.06.002]
10. Lindblad EB. Aluminium compounds for use in vaccines. Immunol Cell Biol 2004;82(5):497-505. [DOI:10.1111/j.0818-9641.2004.01286.x]
11. Agudo-Lopez A, Prieto-Garcia E, Aleman J, Perez C, Diaz-Garcia CV, Parrilla-Rubio L, et al. Mechanistic added value of a trans-Sulfonamide-Platinum-Complex in human melanoma cell lines and synergism with cis-Platin. Mol Cancer 2017;16(1):45. [DOI:10.1186/s12943-017-0618-7]
12. de Biasi AR, Villena-Vargas J, Adusumilli PS. Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 2014;20(21):5384-91. [DOI:10.1158/1078-0432.CCR-14-1298]
13. Hu J, Kinn J, Zirakzadeh AA, Sherif A, Norstedt G, Wikstrom AC, et al. The effects of chemotherapeutic drugs on human monocyte-derived dendritic cell differentiation and antigen presentation. Clin Exp Immunol 2013;172(3):490-9. [DOI:10.1111/cei.12060]
14. Markasz L, Stuber G, Vanherberghen B, Flaberg E, Olah E, Carbone E, et al. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol Cancer Ther 2007;6(2):644-54. [DOI:10.1158/1535-7163.MCT-06-0358]
15. Bergmann-Leitner ES, Abrams SI. Treatment of human colon carcinoma cell lines with anti-neoplastic agents enhances their lytic sensitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 2001;50(9):445-55. [DOI:10.1007/s002620100229]
16. Tseng CW, Hung CF, Alvarez RD, Trimble C, Huh WK, Kim D, et al. Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 2008;14(10):3185-92. [DOI:10.1158/1078-0432.CCR-08-0037]
17. Jackaman C, Majewski D, Fox SA, Nowak AK, Nelson DJ. Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo. Cancer Immunol Immunother 2012;61(12):2343-56. [DOI:10.1007/s00262-012-1307-4]
18. Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother 2011;60(9):1227-42. [DOI:10.1007/s00262-011-1020-8]
19. Monack DM, Bouley DM, Falkow S. Salmonella typhimurium persists within macrophages in the mesenteric lymph nodes of chronically infected Nramp1+/+ mice and can be reactivated by IFNgamma neutralization. J Exp Med 2004;199(2):231-41. [DOI:10.1084/jem.20031319]
20. Mittrucker HW, Kaufmann SH. Immune response to infection with Salmonella typhimurium in mice. J Leukoc Biol 2000;67(4):457-63. [DOI:10.1002/jlb.67.4.457]
21. Mazloomi E, Jazani NH, Shahabi S. A novel adjuvant, mixture of alum and the beta-adrenergic receptor antagonist propranolol, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. Vaccine 2012;30(16):2640-6. [DOI:10.1016/j.vaccine.2012.02.017]
22. Schiller JH, Bittner G. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: effects on tumor neovascularization. Clin Cancer Res 1999;5(12):4287-94. [PubMed]
23. Pan P, Wu Y, Guo ZY, Wang R, Wang YJ, Yuan YF. Antitumor activity and immunomodulatory effects of the intraperitoneal administration of Kanglaite in vivo in Lewis lung carcinoma. J Ethnopharmacol 2012 ;143(2):680-5. [DOI:10.1016/j.jep.2012.07.025]
24. Bansal A, Paliwal PK, Sagi SS, Sairam M. Effect of adjuvants on immune response and protective immunity elicited by recombinant Hsp60 (GroEL) of Salmonella typhi against S. typhi infection. Mol Cell Biochem 2010;337(1-2):213-21. [DOI:10.1007/s11010-009-0301-4]
25. Jazani NH, Worobec E, Shahabi S, Nejad GB. Conjugation of tetanus toxoid with Salmonella typhimurium PTCC 1735 O-specific polysaccharide and its effects on production of opsonizing antibodies in a mouse model. Can J Microbiol 2005;51(4):319-24. [DOI:10.1139/w05-008]
26. Garcon N, Di Pasquale A. From discovery to licensure, the Adjuvant System story. Hum Vaccin Immunother 2017;13(1):19-33. [DOI:10.1080/21645515.2016.1225635]
27. Wen Y, Shi Y. Alum: an old dog with new tricks. Emerg Microbes Infect 2016;5(3):e25. 28. Kool M, Fierens K, Lambrecht BN. Alum adjuvant: some of the tricks of the oldest adjuvant. J Med Microbiol 2012;61(Pt 7):927-34. [DOI:10.1099/jmm.0.038943-0]
28. Bialkowski L, van Weijnen A, Van der Jeught K, Renmans D, Daszkiewicz L, Heirman C, et al. Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours. Sci Rep 2016;6:22509. [DOI:10.1038/srep22509]
29. Kaur S, Sachdeva H, Dhuria S, Sharma M, Kaur T. Antileishmanial effect of cisplatin against murine visceral leishmaniasis. Parasitol Int 2010;59(1):62-9. [DOI:10.1016/j.parint.2009.10.006]
30. Joshi J, Kaur S. To investigate the therapeutic potential of immunochemotherapy with cisplatin + 78 kDa + MPL-A against Leishmania donovani in BALB/c mice. Parasite Immunol 2014;36(1):3-12. [DOI:10.1111/pim.12071]
31. Institute N-NC. The "Accidental" Cure-Platinum-based Treatment for Cancer: The Discovery of Cisplatin 2014 [Available from: https://www.cancer.gov/research/progress/discovery/cisplatin [address]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |